Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 10/8/2025

Management of Autoimmune Hepatitis

Introduction to Treatment

  • The American Association for the Study of Liver Diseases recommends that all patients with active AIH type 1 or type 2 should receive combination therapy with prednisolone (or prednisone) plus azathioprine as first-line treatment, achieving remission in 80-90% of patients 1
  • The European Association for the Study of the Liver suggests starting prednisolone at 60 mg/day for week 1, then taper weekly to maintenance dose 1
  • The treatment guidelines indicate that azathioprine introduction should be delayed by 2 weeks to avoid diagnostic confusion between azathioprine hepatotoxicity and primary non-response 1

Induction and Maintenance Therapy

  • The standard maintenance dose is to maintain azathioprine at 1-2 mg/kg/day as steroid-sparing agent 1
  • Once aminotransferases normalize, reduce prednisolone to 7.5 mg/day, then after 3 months taper to 5 mg/day 1

Pre-Treatment Testing and Vaccinations

  • Check TPMT levels before initiating azathioprine to exclude homozygote deficiency 1
  • Vaccinate against hepatitis A and B in susceptible patients prior to immunosuppression if possible, as recommended by the Hepatology society 2
  • Screen for HBV (HBsAg, anti-HBc, anti-HBs) to identify patients requiring monitoring for reactivation, following the guidelines from Hepatology 2

Treatment Goals and Outcomes

  • The therapeutic endpoint is complete normalization of both ALT and IgG levels, not just improvement, according to the guidelines from Praxis Medical Insights 1

Patient Selection for Treatment

  • Absolute indications for treatment include AST >5 times normal, serum globulins >2 times normal, liver biopsy showing confluent necrosis or bridging necrosis, symptomatic patients, patients with established cirrhosis on biopsy, and younger patients to prevent cirrhosis development, as indicated by the Gut and Journal of Hepatology societies 3, 4, 5

Alternative First-Line and Second-Line Therapies

  • For non-cirrhotic patients at high risk for steroid side effects, budesonide 3 mg three times daily plus azathioprine (1-2 mg/kg/day) is an alternative first-line option that achieves normalization of aminotransferases more frequently with fewer side effects at 6 months, as recommended by Praxis Medical Insights 1
  • Mycophenolate mofetil (MMF) is the preferred second-line agent, particularly for azathioprine intolerance rather than refractory disease, with a starting dose of 1 g daily and maintenance of 1.5-2 g daily, according to Praxis Medical Insights 1

Special Considerations and Populations

  • Type 2 AIH differs from type 1 in several important ways, including primarily occurring in children under 14 years or young adults, with an acute onset in 31-40% of cases, and up to 25% presenting as acute liver failure, as noted by Clinical and Molecular Hepatology 6
  • Despite these differences, the same first-line treatment regimen applies to both type 1 and type 2 AIH, as recommended by Clinical and Molecular Hepatology and Journal of Hepatology 7, 4
  • Azathioprine requires risk-benefit analysis but may be continued if disease control requires it during pregnancy, while MMF is absolutely contraindicated, according to Praxis Medical Insights 1

Monitoring and Common Pitfalls

  • Regular monitoring must include liver enzymes (ALT, AST) and IgG levels, as recommended by Clinical and Molecular Hepatology and Gut 7, 3
  • Stopping treatment too early can result in 50-90% of patients relapsing within 12 months of stopping treatment, as indicated by Gut 8
  • Accepting partial biochemical response is not recommended, as persistent ALT elevation predicts poor outcomes, according to Praxis Medical Insights 1